Literature DB >> 10027829

Inhibition of doxorubicin toxicity in cultured neonatal mouse cardiomyocytes with elevated metallothionein levels.

G W Wang1, Y J Kang.   

Abstract

Controversial results have been reported regarding whether metallothionein (MT) functions in doxorubicin (DOX) detoxification in the heart. To determine unequivocally the role of MT in cardiac protection against the toxicity of DOX, ventricular cardiomyocytes isolated from 1- to 3-day neonatal transgenic mice with high levels of cardiac MT and from nontransgenic control animals were applied. On the 6th day of culturing, MT concentrations in the transgenic cardiomyocytes were about 2-fold higher than those in the nontransgenic cells. DOX was added directly into the cultures. Compared with nontransgenic controls, transgenic cardiomyocytes displayed a significant (p <.05) resistance to DOX cytotoxicity, as measured by morphological alterations, cell viability, and lactate dehydrogenase leakage from the cells. This cytoprotective effect of MT correlated with its inhibition of DOX-induced lipid peroxidation. These observations demonstrate unequivocally that elevation of MT concentrations in the cardiomyocytes of 2-fold higher than normal provides efficient protection against DOX toxicity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10027829

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  13 in total

1.  Immunocytochemical localization of metallothionein and its relation to doxorubicin toxicity in transgenic mouse heart.

Authors:  Z Zhou; Y J Kang
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

2.  An improved protocol for primary culture of cardiomyocyte from neonatal mice.

Authors:  P Sreejit; Suresh Kumar; Rama S Verma
Journal:  In Vitro Cell Dev Biol Anim       Date:  2008-02-23       Impact factor: 2.416

3.  An improved protocol for the isolation and cultivation of embryonic mouse myocytes.

Authors:  Laurel S Rodgers; Daniel C Schnurr; Derrick Broka; Todd D Camenisch
Journal:  Cytotechnology       Date:  2009-05-28       Impact factor: 2.058

Review 4.  Nitric oxide and zinc homeostasis in acute lung injury.

Authors:  Claudette M St Croix; Karanee Leelavaninchkul; Simon C Watkins; Valerian E Kagan; Bruce R Pitt
Journal:  Proc Am Thorac Soc       Date:  2005

5.  Recovery of adriamycin induced mitochondrial dysfunction in liver by selenium.

Authors:  E Taskin; N Dursun
Journal:  Cytotechnology       Date:  2014-10-18       Impact factor: 2.058

6.  Effects of metallothionein on isolated rat heart.

Authors:  Zhongdong Sun; Jiahong Xia; Nianguo Dong; Xinling Du; Yifan Chi; Tienan Yang; Chenyuan Yang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2007-08

7.  ErbB2 overexpression upregulates antioxidant enzymes, reduces basal levels of reactive oxygen species, and protects against doxorubicin cardiotoxicity.

Authors:  Frances Belmonte; Samarjit Das; Polina Sysa-Shah; Vidhya Sivakumaran; Brian Stanley; Xin Guo; Nazareno Paolocci; Miguel A Aon; Masaki Nagane; Periannan Kuppusamy; Charles Steenbergen; Kathleen Gabrielson
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-08-07       Impact factor: 4.733

8.  Effect of O-4-ethoxyl-butyl-berbamine in combination with pegylated liposomal doxorubicin on advanced hepatoma in mice.

Authors:  Bai-Jun Fang; Mei-Li Yu; Shao-Guang Yang; Lian-Ming Liao; Jie-Wen Liu; Robert C-H Zhao
Journal:  World J Gastroenterol       Date:  2004-04-01       Impact factor: 5.742

9.  Metallothionein-independent zinc protection from alcoholic liver injury.

Authors:  Zhanxiang Zhou; Xiuhua Sun; Jason C Lambert; Jack T Saari; Y James Kang
Journal:  Am J Pathol       Date:  2002-06       Impact factor: 4.307

10.  Human resistin in chemotherapy-induced heart failure in humanized male mice and in women treated for breast cancer.

Authors:  Daniel R Schwartz; Erika R Briggs; Mohammed Qatanani; Heloisa Sawaya; Igal A Sebag; Michael H Picard; Marielle Scherrer-Crosbie; Mitchell A Lazar
Journal:  Endocrinology       Date:  2013-08-27       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.